Approximately two out of threebreast cancersare hormone receptor positive, according to the American Cancer Society. This means that the breast cancer cells have receptors for either estrogen or progesterone, which are hormones that enable the growth of cancer.1 Hormone therapy, also called endocrine ...
Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer is the most prevalent type of breast cancer, in which endocrine therapy resistance and distant relapse remain unmet challenges. Accurate molecular classification is urgently required for guiding pre...
辅助内分泌治疗(AET)是激素受体阳性乳腺癌患者的有效治疗策略,可使患者获得显著生存获益,降低复发风险。为了确定最合适的治疗策略,早期乳腺癌辅助内分泌治疗应考虑到患者在诊断时的疾病复发的个体风险和绝经状态。围绝经期人群是乳腺癌高发人群,该文重点评述围绝经期激素受体阳性乳腺癌患者AET相关研究进展。
2. Here we show that in mouse models of hormone-receptor-positive breast cancer, periodic fasting or a fasting-mimicking diet3,4,5 enhances the activity of the endocrine therapeutics tamoxifen and fulvestrant by lowering circulating IGF1, insulin and leptin and by inhibiting AKT–mTOR signalling ...
The choice of breast cancer therapy is based on tumor characteristics such as size, histopathology, estrogen andprogesterone receptorstatus, the level of HER-2 expression, and lymph node infiltration. Therapy includes surgery (lumpectomy, mastectomy), radiotherapy, hormonal therapy, chemotherapy, an...
Clinical advances of everolimus in hormone receptor-positive advanced breast cancer乳腺肿瘤内分泌耐药机制雷帕霉素靶蛋白依维莫司乳腺癌内分泌治疗在乳腺癌综合治疗中逐渐发挥着重要作用,但内分泌治疗耐药问题(原发与继发耐药)是目前亟待解决的重要问题.雌激素受体通路及其他相关信号通路的异常激活是内分泌耐药的主要...
Endocrine therapy remains important in premenopausal women with hormone receptor positive breast cancer. Ovarian ablation, used alone, is effective in delaying recurrence and increasing survival in such women. When added to chemotherapy, it is less clear
: Although hormone receptor positive/HER2-negative (HR +/HER2-) breast cancer is the most diagnosed breast cancer type, the immunologic aspects HR positive breast cancer (BC) has been neglected until recently. The purpose of this paper is to review the current knowledge of the immune environment...
Introduction > Endocrine therapy (ET), alone or in combination with chemotherapy, decreases recurrence and mortality rates in estrogen receptor (ER)- positive early breast cancer (BC) (Lancet 2005;365:1687). > Use of adjuvant tamoxifen (TAM) is a major ET option, particularly for women with ...